Lolita Petit joins Coave Therapeutics as CSO

21 September 2023

French CNS and eye disease genetic medicines firm Coave Therapeutics has appointed Lolita Petit, as chief scientific officer (CSO).

Dr Petit is a genetic medicine expert and will be responsible for leading Coave’s pre-clinical pipeline development as well as expansion of its proprietary ALIGATER (Advanced Vectors-Ligand Conjugates) platform to enhance and optimize both viral and non-viral vectors.

Prior to joining Coave, Dr Petit was the director of gene therapies and delivery at Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals, where she managed the translational gene therapy research team responsible for the characterization and selection of gene therapy candidates in multiple therapeutic areas. Alongside this, Dr Petit led the development and strategic implementation of novel delivery and immunomodulation platforms for ocular gene therapy applications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK